Prescribing Patterns of Oral Antiplatelets in Wales: Evolving Trends From 2005 to 2016

Protty, Majd; Wilkins, Simon J; Hoskins, Hannah C; Dawood, B; Hayes, Joanne

doi:10.2217/fca-2018-0003

Cited by 6 publications

(6 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The declining rate since 2012 is likely attributable to emerging evidence against the use of antiplatelet agents for primary prevention of cardiovascular events, 9,10 and stroke thromboprophylaxis in atrial fibrillation 11 . This is consistent with trends reported in a population in the UK 12 …”

Section: Figuresupporting

confidence: 80%

Contemporary trends in antiplatelet prescription in Australia

Tan

Cieslik

Steele

et al. 2020

Pharmacy Practice and Res

View full text Add to dashboard Cite

Section: Figuresupporting

confidence: 80%

Contemporary trends in antiplatelet prescription in Australia

Tan

Cieslik

Steele

et al. 2020

Pharmacy Practice and Res

View full text Add to dashboard Cite

“…We are aware of few other studies on this topic; however, two recent studies have similarly described a temporal trend of decreasing low-dose aspirin prevalence. In Wales, Protty et al [ 11 ] found that low-dose aspirin prescription rates decreased by 15% from 2005–2016. In a study based on US National Health Interview Survey data from the United States, self-reported aspirin use dropped from 32.6% in 2015 to 30.0% in 2012, with a slighter larger drop seen for primary CVD prevention [ 12 ].…”

Section: Discussionmentioning

confidence: 99%

Trends in the use of oral anticoagulants, antiplatelets and statins in four European countries: a population-based study

Rodrı́guez

Soriano

Abajo

et al. 2021

Eur J Clin Pharmacol

View full text Add to dashboard Cite

Purpose To evaluate time trends in the prevalence of antithrombotic and statin use in four European countries. Methods Using population-based data from the United Kingdom, Denmark, Spain and Italy between 2010 and 2018, we calculated standardized annual prevalence proportions of antithrombotics and statin use, and changes in prevalence proportions (2018 vs. 2010). Results Prevalence proportion of statins increased from 24.8% to 24.6% (UK), 21.0% to 22.3% (Region of Southern Denmark [RSD]), 12.9% to 14.3% (Udine, Italy), and 20.3% to 23.2% (Spain). Prevalence proportions of antithrombotics declined in all four countries: 18.7% to 15.9% (UK; − 2.8% points), 18.9% to 18.1% (RSD; − 0.8% points), 17.7% to 16.6% (Udine; − 1.1% points) and 15.0% to 13.6% (Spain; − 1.4% points). These declines were driven by reductions in low-dose aspirin use: 15.3% to 8.9% (UK; − 6.4% points), 16.3% to 9.5% (RSD; − 6.8% points), 13.5% to 11.6% (Udine; − 1.9% points), and 10.2% to 8.8% (Spain; − 1.4% points). In the UK, low-dose aspirin use declined from 9.1% to 4.3% (− 4.8% points) for primary CVD prevention, and from 49.6% to 36.9% (− 12.7% points) for secondary prevention. Oral anticoagulant use gradually increased but did not fully account for the decrease in low-dose aspirin use. Conclusions Antithrombotic use in the UK, RSD, Udine and Spain declined between 2010 and 2018, driven by a reduction in use of low-dose aspirin that is not completely explained by a gradual increase in OAC use. Use of statins remained constant in the UK, and increased gradually in the RSD, Udine and Spain.

show abstract

“…There is no reason therefore why two, or perhaps all three of the preventives should not be taken for protection against vascular disease events. At the same time, it seems unfortunate that there is a marked year‐on‐year decline in the prescribing of aspirin in the UK in favor of newer and more expensive antiplatelet and antithrombotic agents, 29 for none of which is there evidence suggestive of a reduction in cancer.…”

Section: Discussionmentioning

confidence: 99%

Better than any pill—and no side effects! Healthy lifestyles, statins, and aspirin

et al. 2020

View full text Add to dashboard Cite

Behaviors which are associated with the preservation of health include nonsmoking, regular exercise, a low body weight, a healthy diet, and a low alcohol intake. Together, as a healthy lifestyle, these have been shown to be associated with marked protection against a wide range of diseases: diabetes, vascular disease, cancer, and dementia. On the other hand, the protection associated with statins and aspirin, the two most commonly used preventive drugs, is limited to vascular disease and, probably for aspirin, cancer. These are not alternative prophylactics and any two, or all three-a healthy lifestyle, a statin, and aspirin-can reasonably be taken together. Only a small proportion of the members of the community follow a healthy lifestyle. Yet a small increase in the uptake of the healthy behaviors throughout the community can be shown to have relatively large effects on the incidence of disease. There is therefore an urgent need for health promotion activities across the whole community to be greatly increased and for new challenging and encouraging strategies to be devised and tested.

show abstract

Prescribing Patterns of Oral Antiplatelets in Wales: Evolving Trends From 2005 to 2016

Abstract: This first-look analysis of real-life antiplatelet data demonstrates a decrease in the overall prescribing costs with varying patterns. This may aid policy-makers in reviewing funding strategies.

Cited by 6 publications

References 23 publications

Contemporary trends in antiplatelet prescription in Australia

Contemporary trends in antiplatelet prescription in Australia

Trends in the use of oral anticoagulants, antiplatelets and statins in four European countries: a population-based study

Better than any pill—and no side effects! Healthy lifestyles, statins, and aspirin

Contact Info

Product

Resources

About